Podcasts

Professor Richard Furie (Northwell Health, New York) and Professor Victoria Werth (University of Pennsylvania) join the latest Lupus Forum podcast to discuss efficacy and safety of belimumab or telitacicept as sequential treatment after rituximab in LN and the efficacy and safety of obinutuzumab in LN.

Join Professors Ed Vital and Brad Rovin as they summarise the "Challenges in LN" webinar, covering the importance of early diagnosis, implications of delayed diagnosis, and barriers to early diagnosis associated with lupus nephritis.

Professor Vibeke Stand (Stanford University) and Professor Eric Morand (Monash University) join the latest Lupus Forum podcast to discuss LLDAS and remission in SLE patients with HDAS, as well as the latest APLAR treatment consensus for LN.

Steering Committee member Professor Maria Dall’Era, Professor of Medicine and Chief of the Division of Rheumatology at the of University of California, San Francisco, USA, is joined by fellow member Professor Brad Rovin, who is Lee A. Hebert Professor of Nephrology and Medical Director at Ohio State University Clinical Research Management Institute, Columbus, Ohio, on the latest Lupus Forum podcast.

Together, they discuss the efficacy and safety of a voclosporin-based triple immunosuppressive regimen and summarise the latest ACR guidance to screen, treat, and manage lupus nephritis.

Steering Committee member Professor Victoria Werth, who is Chief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital, Pennsylvania, USA, is joined by fellow member Professor Chi-Chiu Mok, who is Chief of the Division of Rheumatology, Department of Medicine, Tuen Mun Hospital, Hong Kong, on the latest Lupus Forum podcast.

Together, they discuss the efficacy and safety of iberdomide in CLE, as well as the efficacy and safety of SGLT2i vs. DPP4i for the primary prevention of cardiovascular disease and renal events in SLE and comorbid type 2 diabetes.

Steering Committee members Professor Ed Vital, who is a Professor in Autoimmune Connective Tissue Diseases and Honorary Consultant Rheumatologist, at Leeds Teaching Hospitals NHS Trust, UK, is joined by Professor Richard Furie, who is Chief of the Division of Rheumatology at the Department of Medicine, Northwell Health, New York, and Professor of Medicine at the Zucker School of Medicine at Hofstra/Northwell, and Professor Liz Lightstone, from the Imperial College Healthcare NHS Trust Renal and Transplant Centre, Hammersmith, London, on the latest Lupus Forum podcast.

Together, they discuss defining ANA-associated arthritis and proposing new basket trial groupings, as well as evaluating the achievement of EULAR/ERA-EDTA treatment targets in lupus nephritis and the need for therapy adjustments.